Evidence map›Paper›PMID 29713640›Full record

Trial reportBioMed research international2018

The Use of Ropivacaine in Therapeutic Treatment of Oral Aphthosis.

Giulio Gasparini, Gianmarco Saponaro, Daniela Gasparini, Enrico Foresta, Camillo Azzuni, Alessia Adduci, Roberto Boniello, Alessandro Moro, Paolo De Angelis, Francesco Di Nardo and 5 more

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Giulio GaspariniUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.ORCID 0000-0001-5091-5178
Gianmarco SaponaroUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.ORCID 0000-0001-9760-2419
Daniela GaspariniUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Enrico ForestaUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Camillo AzzuniUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Alessia AdduciDepartment of Anesthesiology and Intensive Care Medicine, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Roberto BonielloUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Alessandro MoroUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Paolo De AngelisUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Francesco Di NardoInstitute of Public Health, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.ORCID 0000-0003-3655-0904
Giuseppe DamatoUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Piero DonedduUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Mattia TodaroUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Umberto GaragiolaDepartment of Biomedical, Surgical and Oral Sciences, School of Dentistry, University of Milan, Milan, Italy.ORCID 0000-0002-3256-6725
Sando PeloUOC Maxillo Facial Surgery, Policlinico Gemelli Foundation, Catholic University Medical School, Rome, Italy.
Agostino Gemelli University Polyclinic · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of anaesthetic drugs in the treatment of oral aphthosis is one of the pharmaceutical possibilities that a doctor can use for the most painful forms. Normally, Lidocaine or Diclofenac is used to treat this disease, but they can be used for a very limited time and so they are of little practical use. In this study, the authors have used Ropivacaine whose pharmaceutical kinetics allows the analgesic effect to be active for 60 to 90 minutes. In our research, we compared 8 groups of patients who have been given 3 principal pharmaceutical products: one group was given an anaesthetic drug, one had a topical medication administered which is often used for the treatment of aphthous lesions, and the last group was given a multivitamin. These pharmaceutical products were used alone and in various possible combinations in the 8 groups. The results of this study are very interesting and show that in all the groups that used anaesthetics there was more satisfaction on the patients' part because their pain level became more manageable right after the first application of the drug and the patients could carry on with their normal lives.

Indexed as

AdultAmidesAnesthetics, LocalFemaleHumansMaleRopivacaineStomatitis, AphthousAmidesAnesthetics, LocalRopivacaine

Identifiers

PMID29713640
PMCPMC5866890
OpenAlexW2791136632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.